DGNOF

$0.28-$0.01 (-2.21%)live

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

52-week range

$0.13 – $0.30

85% from low

Exchange

OTC Link

Change+$0.01

DIAGNOS INC

No one on the platform currently holds DGNOF.

Institutions holding (13F)

No tracked institution reports a position in DGNOF as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Execution date	Ratio
2019-04-24	1-for-10reverse
2014-07-16	1.5-for-1

No one on the platform has traded DGNOF yet.

Emerging Growth Research@Emerging_Growth_ResearchJun 9
$DGNOF @EmergingGrowth1 Emerging Growth Research releases a flash report on DIAGNOS $DGNOF. To read the full version of the flash report go here: https://emerginggrowth.com/wp-content/uploads/2026/06/DIAGNOS-Inc.-DGNOF-Flash-Report-6.3.2026.pdf Emerging Growth Research noted that DIAGNOS is positioned to benefit from several favorable long-term trends, including the aging global population, increasing prevalence of diabetes-related eye disease, shortages of eye-care specialists, and growing adoption of artificial intelligence in healthcare diagnostics.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.